开云app官网登录入口网页版-官方正版

#KEYNOTE#

43篇内容 | 1514人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703457, encodeId=78a11e034579c, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, objectType=article, longId=726015, objectId=0c7fe2601525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7fe2601525, replyNumber=0, likeNumber=71, createdTime=2022-11-27, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7fe2601525, moduleTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c7fe2601525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703456, encodeId=87801e03456dd, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=84, createdTime=2022-11-22, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703450, encodeId=b9be1e034500b, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=85, createdTime=2022-03-21, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703454, encodeId=cb361e034544f, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, objectType=article, longId=301715, objectId=f4ef301e1547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ef301e1547, replyNumber=0, likeNumber=98, createdTime=2022-09-16, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ef301e1547, moduleTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f4ef301e1547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703455, encodeId=41a31e03455f3, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, objectType=article, longId=723564, objectId=5743e2356484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5743e2356484, replyNumber=0, likeNumber=77, createdTime=2023-01-27, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5743e2356484, moduleTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5743e2356484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703453, encodeId=5e061e0345358, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=99, createdTime=2022-09-20, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703447, encodeId=4a2d1e0344760, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=81, createdTime=2022-05-16, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703452, encodeId=80181e03452b6, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=78, createdTime=2021-12-09, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703451, encodeId=32921e03451ce, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）, objectType=article, longId=217406, objectId=cd4321e40665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd4321e40665, replyNumber=0, likeNumber=96, createdTime=2022-07-31, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd4321e40665, moduleTitle=NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cd4321e40665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703448, encodeId=702a1e034487b, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=84, createdTime=2022-03-04, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703442, encodeId=47161e0344229, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）, objectType=article, longId=205394, objectId=2e7120539485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e7120539485, replyNumber=0, likeNumber=89, createdTime=2021-07-03, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e7120539485, moduleTitle=Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e7120539485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703449, encodeId=dcf91e03449bc, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, objectType=article, longId=213761, objectId=ae12213e61f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae12213e61f4, replyNumber=0, likeNumber=94, createdTime=2021-11-15, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae12213e61f4, moduleTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae12213e61f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703445, encodeId=249b1e03445ff, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, objectType=article, longId=207203, objectId=134820e203ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134820e203ba, replyNumber=0, likeNumber=93, createdTime=2021-11-14, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134820e203ba, moduleTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=134820e203ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703446, encodeId=bc531e0344629, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, objectType=article, longId=211056, objectId=5c43211056a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c43211056a3, replyNumber=0, likeNumber=97, createdTime=2021-08-27, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c43211056a3, moduleTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5c43211056a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703443, encodeId=3b921e03443b5, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=85, createdTime=2021-04-23, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703444, encodeId=1d6e1e0344424, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, objectType=article, longId=206606, objectId=61362066067d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61362066067d, replyNumber=0, likeNumber=81, createdTime=2021-07-21, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61362066067d, moduleTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=61362066067d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703440, encodeId=60d41e0344052, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, objectType=article, longId=193109, objectId=bc64193109cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc64193109cc, replyNumber=0, likeNumber=71, createdTime=2020-10-05, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc64193109cc, moduleTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bc64193109cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703441, encodeId=491f1e0344118, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01, objectType=article, longId=201027, objectId=4d2c20102e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d2c20102e70, replyNumber=0, likeNumber=91, createdTime=2021-07-07, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2c20102e70, moduleTitle=尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4d2c20102e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703438, encodeId=79861e034384e, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, objectType=article, longId=183247, objectId=74bf18324ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bf18324ece, replyNumber=0, likeNumber=101, createdTime=2020-10-08, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bf18324ece, moduleTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74bf18324ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703439, encodeId=15b61e034397f, content=<a href='/topic/show?id=2fdf10464e6' target=_blank style='color:#2F92EE;'>#KEYNOTE#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=91, createdTime=2020-04-12, rootId=0, userName=tm10051991, userId=94e330506057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

KEYNOTE

2020-05-29

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）

2022-11-27

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-11-22

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2022-03-21

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）

2022-09-16

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）

2023-01-27

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-09-20

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2022-05-16

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2021-12-09

医者仁心 (审核中...)

前往app查看评论内容

#KEYNOTE#

NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）

2022-07-31

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2022-03-04

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）

2021-07-03

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。

2021-11-15

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）

2021-11-14

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果

2021-08-27

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-04-23

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）

2021-07-21

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）

2020-10-05

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01

2021-07-07

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164

2020-10-08

tm10051991 (审核中...)

前往app查看评论内容

#KEYNOTE#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-04-12

科室
- - 订阅+
  - 更多科室
工具
服务